Dr Sharman
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood 2024;144(18):1924-35. Abstract
Barr PM et al. Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 2022;6(11):3440-50. Abstract
Brown JR et al. Extended follow-up of alpine randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL). ASH 2023;Abstract 202.
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Fürstenau M et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2024;25(6):744-59. Abstract
Langerbeins P et al. Ibrutinib in early-stage chronic lymphocytic leukemia: The randomized, placebo-controlled, double-blind, phase III CLL12 trial. J Clin Oncol 2024;[Online ahead of print]. Abstract
Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN. ASH 2023;Abstract 636.
Tam CS et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial. Lancet Oncol 2022;23(8):1031-43. Abstract
Dr Rogers
Ahn IE et al. A phase 2 study of zanubrutinib and venetoclax (ZV) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). ASH 2024;Abstract 1874.
Brown JR et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial. ASH 2024;Abstract 1009.
Liu J et al. Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy. Blood 2024;143(18):1825-36. Abstract
Ma S et al. Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17P) and/or TP53: preliminary results from sequoia arm D. EHA 2024;Abstract S160.
Niemann CU et al. First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): Glow study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis. ASH 2024;Abstract 1871.
Niemann CU et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24(12):1423-33. Abstract
Rogers K et al. 7-year update on a phase 2 trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL. EHA 2024;Abstract S162.
Soumerai JD et al. Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (boven) in treatment-naïve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400). ASH 2024;Abstract 1867.
Soumerai JD et al. Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: Data from an ongoing phase 1/1b study BGB-11417-101. ASH 2024;Abstract 1012.
Soumerai JD et al. Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (boven) in previously untreated patients with CLL/SLL. ICML 2023;Abstract 153
Woyach JA et al. Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance). ASCO 2023;Abstract 7500.
Dr Awan
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. EHA 2022;Abstract S148.
Al-Sawaf O et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020:21(9):1188-200. Abstract
Awan FT et al. International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL. Blood Adv 2022;6(18):5516-25. Abstract
Brown JR et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388(4):319-32. Abstract
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Fischer K et al. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hemtology Am Soc Hematol Educ Program 2020;2020(1):357-62. Abstract
Goede V et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA 2018;Abstract S151.
Mato AR et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389(1):33-44. Abstract
Shanafelt TD et al. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial. Blood 2022;140(2):112-20. Abstract
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. ASCO 2022;Abstract 7539.
Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 5-year follow-up of ELEVATE-TN. EHA 2022;Abstract P666.
Tam CS et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial. Lancet Oncol 2022;23(8):1031-43. Abstract
Woyach J et al. Updated analysis of BELLWAVE-001: A phase 1/2 open-label dose-expansion study of the efficacy and safety of nemtabrutinib for the treatment of B-cell malignancies. EHA 2023;Abstract P628.
Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract
Dr Fakhri
Woyach JA et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non–hodgkin lymphoma. Cancer Discov 2024;14(1):66-75. Abstract
Woyach JA et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study. ASH 2023;Abstract 325.
Woyach JA et al. Long-term results of alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood 2021;138(S1):639. Abstract
Dr Wierda
Kater AP et al. Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort. iwCLL 2023;Abstract 1546171.
Parrondo R et al. Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study. EHA 2024;Abstract S157.
Siddiqi T et al. First-line ibrutinib (ibr) + venetoclax (ven) for patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): efficacy and safety results from captivate MRD cohort. EHA 2024;Abstract S158.
Siddiqi T et al. Lisocabtagene maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004. ASH 2023;Abstract 330.
Wierda WG et al. TRANSCEND CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with R/R CLL/SLL. ICML 2021;Abstract 86.